Effective anti-infectives for medically unmet diseases? Ask Novabiotics

17/06/2016 - 2 minutes

Toulouse was fun, but it’s time to go somewhere new!

Fan of the Highlands, the landscapes that made the Harry Potter scenery much more exciting and the Loch Ness Monster? I’m just asking because this week we are going to Scotland!

Aberdeen is our final destination, and we are visiting Novabiotics, our Biotech of the Week!

novabiotics_logo_botw

City: Aberdeen (Scotland – United Kingdom)

Founded: 2004

Related Content

Employees: 20

Financial Data: €22M Total Raised (as of 6/2016)

CEO: Deborah O’Neill

deborah_oneill_novabiotics_ceo_300x218

Mission: NovaBiotic is developing first-in-class therapies for difficult-to-treat diseases, such as antibiotic-resistant infections and cystic fibrosis. Until now, it has raised over £17M in private funding.

Along with 4 candidates currently in clinical development, NovaBiotics also has a proprietary strategy for drug design up its sleeve. It can develop novel antifungal and antibacterial molecules (peptides and aminothiols) that kill bacteria,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member